Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the Invesco Large Cap Value ETF (PWV), a passively managed exchange traded fund launched on 03/03 ...

This was the stock's third consecutive day of gains.

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...

The global dermal fillers market share analysis is poised for significant growth, with total sales projected to reach USD 6,466.6 million by 2025. This surge is fueled by the increasing demand for non ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...